Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): What have we learned so far?

Cancer Treatment Reviews

Volumn 33, Issue 4, 2007, Pages 391-406

  Fischer, Barbara ^a   Marinov, Marin ^a   Arcaro, Alexandre ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

c Kit; Epidermal growth factor receptor; Gefitinib; Gleevec; Insulin like growth factor receptor; Mammalian target of rapamycin; Phosphoinositide 3 kinase; Ras; Receptor tyrosine kinase; Small cell lung cancer

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; GEFITINIB; GROWTH FACTOR; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY DC101; NVP ADW 742; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; SEMAXANIB; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; THALIDOMIDE; TIPIFARNIB; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CIGARETTE SMOKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; INHIBITION KINETICS; LUNG SMALL CELL CANCER; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 34248578455     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.01.006     Document Type: Review

References (213)

1. Cooper S., and Spiro S.G. Small cell lung cancer: treatment review. Respirology 11 (2006) 241-248
2. Jackman D.M., and Johnson B.E. Small-cell lung cancer. Lancet 366 (2005) 1385-1396
3. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
4. Heasley L.E. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20 (2001) 1563-1569
5. Sell C., Rubini M., Rubin R., et al. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 90 (1993) 11217-11221
6. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 9 (2005) 753-768
7. Hofmann F., and Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 10 (2005) 1041-1047
8. Niklinski J., and Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev 4 (1995) 129-138
9. Quinn K.A., Treston A.M., Unsworth E.J., et al. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271 (1996) 11477-11483
10. Nakanishi Y., Mulshine J.L., Kasprzyk P.G., et al. Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro. J Clin Invest 82 (1988) 354-359
11. Rotsch M., Maasberg M., Erbil C., et al. Characterization of insulin-like growth factor I receptors and growth effects in human lung cancer cell lines. J Cancer Res Clin Oncol 118 (1992) 502-508
12. Reeve J.G., Morgan J., Schwander J., and Bleehen N.M. Role for membrane and secreted insulin-like growth factor-binding protein-2 in the regulation of insulin-like growth factor action in lung tumors. Cancer Res 53 (1993) 4680-4685
13. Macaulay V.M., Everard M.J., Teale J.D., et al. Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. Cancer Res 50 (1990) 2511-2517
14. Izycki T., Chyczewska E., Naumnik W., and Ossolinska M. Serum levels of IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. Oncol Res 16 (2006) 49-54
15. Yu H., Spitz M.R., Mistry J., et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91 (1999) 151-156
16. Unsal E., Koksal D., Yurdakul A.S., Atikcan S., and Cinaz P. Analysis of insulin like growth factor 1 and insulin like growth factor binding protein 3 levels in bronchoalveolar lavage fluid and serum of patients with lung cancer. Respir Med 99 (2005) 559-565
17. Lee D.Y., Kim S.J., and Lee Y.C. Serum insulin-like growth factor (IGF)-I and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14 (1999) 401-404
18. Krystal G.W., Sulanke G., and Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1 (2002) 913-922
19. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
20. Mitsiades C.S., Mitsiades N.S., McMullan C.J., et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
21. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 3 (2004) 527-535
22. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11 (2005) 1563-1571
23. Camirand A., and Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90 (2004) 1825-1829
24. Ronnstrand L. Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci 61 (2004) 2535-2548
25. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 (2002) 1692-1703
26. Sekido Y., Obata Y., Ueda R., et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51 (1991) 2416-2419
27. Hibi K., Takahashi T., Sekido Y., et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6 (1991) 2291-2296
28. Rygaard K., Nakamura T., and Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br J Cancer 67 (1993) 37-46
29. Matsuda R., Takahashi T., Nakamura S., et al. Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues. Am J Pathol 142 (1993) 339-346
30. Papadimitriou C.A., Topp M.S., Serve H., et al. Recombinant human stem cell factor does exert minor stimulation of growth in small cell lung cancer and melanoma cell lines. Eur J Cancer 31A (1995) 2371-2378
31. Krystal G.W., Hines S.J., and Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56 (1996) 370-376
32. Wang W.L., Healy M.E., Sattler M., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 19 (2000) 3521-3528
33. Krystal G.W., Honsawek S., Litz J., and Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6 (2000) 3319-3326
34. Kijima T., Maulik G., Ma P.C., et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 62 (2002) 6304-6311
35. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
36. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
37. Hirota S. Gastrointestinal stromal tumors: their origin and cause. Int J Clin Oncol 6 (2001) 1-5
38. Nakata Y., Kimura A., Katoh O., et al. c-kit point mutation of extracellular domain in patients with myeloproliferative disorders. Br J Haematol 91 (1995) 661-663
39. Bondzi C., Litz J., Dent P., and Krystal G.W. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells. Cell Growth Differ 11 (2000) 305-314
40. Krystal G.W., Honsawek S., Kiewlich D., et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61 (2001) 3660-3668
41. Naeem M., Dahiya M., Clark J.I., Creech S.D., and Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 33 (2002) 1182-1187
42. Micke P., Basrai M., Faldum A., et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 9 (2003) 188-194
43. Potti A., Moazzam N., Ramar K., et al. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 14 (2003) 894-897
44. Blackhall F.H., Pintilie M., Michael M., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 2241-2247
45. Rossi G., Cavazza A., Marchioni A., et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 16 (2003) 1041-1047
46. Boldrini L., Ursino S., Gisfredi S., et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 10 (2004) 4101-4108
47. Rohr U.P., Rehfeld N., Pflugfelder L., et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 111 (2004) 259-263
48. Soria J.C., Johnson B.E., and Chevalier T.L. Imatinib in small cell lung cancer. Lung Cancer 41 Suppl 1 (2003) S49-S53
49. Sihto H., Sarlomo-Rikala M., Tynninen O., et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 23 (2005) 49-57
50. Krug L.M., Crapanzano J.P., Azzoli C.G., et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial. Cancer 103 (2005) 2128-2131
51. Tamborini E., Bonadiman L., Negri T., et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 10 (2004) 8214-8219
52. Dy G.K., Miller A.A., Mandrekar S.J., et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann Oncol 16 (2005) 1811-1816
53. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 5880-5887
54. Altundag O., Altundag K., Boruban C., Silay Y.S., and Turen S. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a Phase II clinical trial. Cancer 104 (2005) 2033-2034 author reply 2034
55. Decaudin D., de Cremoux P., Sastre X., et al. In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy. Int J Cancer 113 (2005) 849-856
56. Litz J., Sakuntala Warshamana-Greene G., Sulanke G., Lipson K.E., and Krystal G.W. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46 (2004) 283-291
57. Wolff N.C., Randle D.E., Egorin M.J., Minna J.D., and Ilaria Jr. R.L. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 10 (2004) 3528-3534
58. Eswarakumar V.P., Lax I., and Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 16 (2005) 139-149
59. Grose R., and Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16 (2005) 179-186
60. Huang A., and Wright J.A. Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene 9 (1994) 491-499
61. Shaulian E., Resnitzky D., Shifman O., et al. Induction of Mdm2 and enhancement of cell survival by bFGF. Oncogene 15 (1997) 2717-2725
62. Konig A., Menzel T., Lynen S., et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 11 (1997) 258-265
63. Cohen-Jonathan E., Toulas C., Monteil S., et al. Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells. Cancer Res 57 (1997) 1364-1370
64. Miyake H., Hara I., Gohji K., et al. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 123 (1998) 121-126
65. Song S., Wientjes M.G., Gan Y., and Au J.L. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci USA 97 (2000) 8658-8663
66. Bikfalvi A., Klein S., Pintucci G., and Rifkin D.B. Biological roles of fibroblast growth factor-2. Endocr Rev 18 (1997) 26-45
67. Seghezzi G., Patel S., Ren C.J., et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 141 (1998) 1659-1673
68. Ruotsalainen T., Joensuu H., Mattson K., and Salven P. High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. Cancer Epidemiol Biomarkers Prev 11 (2002) 1492-1495
69. Pardo O.E., Arcaro A., Salerno G., et al. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells. Oncogene 20 (2001) 7658-7667
70. Pardo O.E., Arcaro A., Salerno G., et al. Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem 277 (2002) 12040-12046
71. Pardo O.E., Lesay A., Arcaro A., et al. Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol 23 (2003) 7600-7610
72. Pardo O.E., Wellbrock C., Khanzada U.K., et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 25 (2006) 3078-3088
73. Laird A.D., Vajkoczy P., Shawver L.K., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60 (2000) 4152-4160
74. Naumova E., Ubezio P., Garofalo A., et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 12 (2006) 1839-1849
75. Byrne A.M., Bouchier-Hayes D.J., and Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9 (2005) 777-794
76. Takigawa N., Segawa Y., Fujimoto N., Hotta K., and Eguchi K. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Res 18 (1998) 1251-1254
77. Mall J.W., Schwenk W., Philipp A.W., et al. Serum vascular endothelial growth factor levels correlate better with tumour stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 7 (2002) 99-102
78. Salven P., Ruotsalainen T., Mattson K., and Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 79 (1998) 144-146
79. Hasegawa Y., Takanashi S., Okudera K., et al. Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med 44 (2005) 26-34
80. Lund E.L., Thorsen C., Pedersen M.W., Junker N., and Kristjansen P.E. Relationship between vessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in small cell lung cancer in vivo and in vitro. Clin Cancer Res 6 (2000) 4287-4291
81. Fontanini G., Faviana P., Lucchi M., et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86 (2002) 558-563
82. Stefanou D., Batistatou A., Arkoumani E., Ntzani E., and Agnantis N.J. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in small-cell and non-small-cell lung carcinomas. Histol Histopathol 19 (2004) 37-42
83. Mall J.W., Philipp A.W., Mall W., and Pollmann C. Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy. Angiogenesis 5 (2002) 11-13
84. Stephens T.D., Bunde C.J., and Fillmore B.J. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59 (2000) 1489-1499
85. Lee S.M., James L.E., et al. A phase II study of carboplatin/etoposide with thalidomide in small cell lung cancer (SCLC). Proc Am Soc Clin Oncol 21 (2002) 313a
86. Bamias A., and Dimopoulos M.A. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Invest Drugs 14 (2005) 45-55
87. Teo S.K. Properties of thalidomide and its analogues: implications for anticancer therapy. Aaps J 7 (2005) E14-E19
88. Kalmadi S., Davis M., Dowlati A., et al. Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid(R)) in patients with advanced solid tumors. Invest New Drugs (2006)
89. Warfel N.A., Lepper E.R., Zhang C., Figg W.D., and Dennis P.A. Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. Clin Cancer Res 12 (2006) 3502-3509
90. Blaes F. Immunotherapeutic approaches to paraneoplastic neurological disorders. Expert Opin Invest Drugs 9 (2000) 727-733
91. Tanno S., Ohsaki Y., Nakanishi K., Toyoshima E., and Kikuchi K. Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46 (2004) 11-19
92. Yano S., Muguruma H., Matsumori Y., et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res 11 (2005) 8789-8798
93. Kozin S.V., Boucher Y., Hicklin D.J., et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 61 (2001) 39-44
94. Tong R.T., Boucher Y., Kozin S.V., et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64 (2004) 3731-3736
95. Pavelic K., Banjac Z., Pavelic J., and Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 13 (1993) 1133-1137
96. Haeder M., Rotsch M., Bepler G., et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res 48 (1988) 1132-1136
97. Sakiyama S., Nakamura Y., and Yasuda S. Expression of epidermal growth factor receptor gene in cultured human lung cancer cells. Jpn J Cancer Res 77 (1986) 965-969
98. Kaseda S., Ueda M., Ozawa S., et al. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J Surg Oncol 42 (1989) 16-20
99. Gamou S., Hunts J., Harigai H., et al. Molecular evidence for the lack of epidermal growth factor receptor gene expression in small cell lung carcinoma cells. Cancer Res 47 (1987) 2668-2673
100. Soderdahl G., Betsholtz C., Johansson A., Nilsson K., and Bergh J. Differential expression of platelet-derived growth factor and transforming growth factor genes in small- and non-small-cell human lung carcinoma lines. Int J Cancer 41 (1988) 636-641
101. Damstrup L., Rygaard K., Spang-Thomsen M., and Poulsen H.S. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res 52 (1992) 3089-3093
102. Damstrup L., Rude Voldborg B., Spang-Thomsen M., Brunner N., and Skovgaard Poulsen H. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 78 (1998) 631-640
103. Tanno S., Ohsaki Y., Nakanishi K., Toyoshima E., and Kikuchi K. Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib (Iressa, ZD1839). Oncol Rep 12 (2004) 1053-1057
104. Araki J., Okamoto I., Suto R., Ichikawa Y., and Sasaki J. Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer. Lung Cancer 48 (2005) 141-144
105. Schneider J., Presek P., Braun A., et al. p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 80 (1999) 1987-1994
106. Parra H.S., Cavina R., Latteri F., et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 91 (2004) 208-212
107. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
108. Okamoto I., Araki J., Suto R., et al. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann Oncol 17 (2006) 1028-1029
109. Zakowski M.F., Ladanyi M., and Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355 (2006) 213-215
110. Scaltriti M., and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12 (2006) 5268-5272
111. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 4241s-4244s
112. Kollmannsberger C., Schittenhelm M., Honecker F., et al. A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol 17 (2006) 1007-1013
113. Hirota N., Ueda M., Ozawa S., Abe O., and Shimizu N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res 49 (1989) 7106-7109
114. Suwa T., Ueda M., Jinno H., et al. Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells. Anticancer Res 19 (1999) 4161-4165
115. Baselga J., and Hammond L.A. HER-targeted tyrosine-kinase inhibitors. Oncology 63 Suppl 1 (2002) 6-16
116. Wakeling A.E., Barker A.J., Davies D.H., et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res Treat 38 (1996) 67-73
117. Manegold C. Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies. Adv Exp Med Biol 532 (2003) 247-252
118. Asahina H., Yamazaki K., Kinoshita I., et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95 (2006) 998-1004
119. Nakamura Y., Oka M., Soda H., et al. Gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65 (2005) 1541-1546
120. Moore A.M., Einhorn L.H., Estes D., et al. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer 52 (2006) 93-97
121. Meert A.P., Martin B., Paesmans M., et al. The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 89 (2003) 959-965
122. Hirsch F.R., Franklin W.A., Veve R., Varella-Garcia M., and Bunn Jr. P.A. HER2/neu expression in malignant lung tumors. Semin Oncol 29 (2002) 51-58
123. Bunn Jr. P.A., Helfrich B., Soriano A.F., et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 7 (2001) 3239-3250
124. Hirsch F.R., Helfrich B., Franklin W.A., et al. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines. Clin Breast Cancer 3 Suppl 1 (2002) 12-16
125. Giltnane J.M., Murren J.R., Rimm D.L., and King B.L. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology 49 (2006) 161-169
126. Micke P., Hengstler J.G., Ros R., et al. c-erbB-2 expression in small-cell lung cancer is associated with poor prognosis. Int J Cancer 92 (2001) 474-479
127. Yoshimura C., Nomura S., Yamaoka M., et al. Analysis of serum ErbB-2 protein and HLA-DRB1 in Japanese patients with lung cancer. Cancer Lett 152 (2000) 87-95
128. Potti A., Ganti A.K., Koch M., Mehdi S.A., and Levitt R. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia. Lung Cancer 34 (2001) 227-232
129. Potti A., Willardson J., Forseen C., et al. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma. Lung Cancer 36 (2002) 257-261
130. Sliwkowski M.X., Lofgren J.A., Lewis G.D., et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (1999) 60-70
131. Ma P.C., Maulik G., Christensen J., and Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22 (2003) 309-325
132. Bredin C.G., Liu Z., Hauzenberger D., and Klominek J. Growth-factor-dependent migration of human lung-cancer cells. Int J Cancer 82 (1999) 338-345
133. Maulik G., Kijima T., Ma P.C., et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8 (2002) 620-627
134. Takigawa N., Segawa Y., Maeda Y., Takata I., and Fujimoto N. Serum hepatocyte growth factor/scatter factor levels in small cell lung cancer patients. Lung Cancer 17 (1997) 211-218
135. Jafri N.F., Ma P.C., Maulik G., and Salgia R. Mechanisms of metastasis as related to receptor tyrosine kinases in small-cell lung cancer. J Environ Pathol Toxicol Oncol 22 (2003) 147-165
136. Maulik G., Madhiwala P., Brooks S., et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 6 (2002) 539-553
137. Ma P.C., Kijima T., Maulik G., et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 63 (2003) 6272-6281
138. Webb C.P., Hose C.D., Koochekpour S., et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res 60 (2000) 342-349
139. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., and Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4 (2005) 988-1004
140. Shaw R.J., and Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 (2006) 424-430
141. Moore S.M., Rintoul R.C., Walker T.R., et al. The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58 (1998) 5239-5247
142. Razzini G., Berrie C.P., Vignati S., et al. Novel functional PI 3-kinase antagonists inhibit cell growth and tumorigenicity in human cancer cell lines. FASEB J 14 (2000) 1179-1187
143. Sethi T., Rintoul R.C., Moore S.M., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 5 (1999) 662-668
144. Hodkinson P.S., Elliott T., Wong W.S., et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 13 (2006) 1776-1788
145. Tsurutani J., West K.A., Sayyah J., Gills J.J., and Dennis P.A. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65 (2005) 8423-8432
146. Kraus A.C., Ferber I., Bachmann S.O., et al. In vitro chemo- and radio-resistance in small cell lung cancer correlates with cell adhesion and constitutive activation of AKT and MAP kinase pathways. Oncogene 21 (2002) 8683-8695
147. Yokomizo A., Tindall D.J., Drabkin H., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17 (1998) 475-479
148. Forgacs E., Zochbauer-Muller S., Olah E., and Minna J.D. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res 7 (2001) 6-13
149. Chen Y.L., Law P.Y., and Loh H.H. Inhibition of akt/protein kinase B signaling by naltrindole in small cell lung cancer cells. Cancer Res 64 (2004) 8723-8730
150. Arcaro A., Khanzada U.K., Vanhaesebroeck B., et al. Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 21 (2002) 5097-5108
151. West K.A., Brognard J., Clark A.S., et al. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 111 (2003) 81-90
152. Tsurutani J., Castillo S.S., Brognard J., et al. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis 26 (2005) 1182-1195
153. Jin Z., Gao F., Flagg T., and Deng X. Nicotine induces multi-site phosphorylation of Bad in association with suppression of apoptosis. J Biol Chem 279 (2004) 23837-23844
154. Xin M., and Deng X. Nicotine inactivation of the proapoptotic function of Bax through phosphorylation. J Biol Chem 280 (2005) 10781-10789
155. Belyanskaya L.L., Hopkins-Donaldson S., Kurtz S., et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 117 (2005) 755-763
156. Wu C., Wangpaichitr M., Feun L., et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4 (2005) 25
157. Pandya K, Levy D, Hidalgo M. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. In: A preliminary report ASCO annual meeting proceedings, Abstract 7005 2005.
158. Mitin N., Rossman K.L., and Der C.J. Signaling interplay in Ras superfamily function. Curr Biol 15 (2005) R563-R574
159. Satoh T., and Kaziro Y. Ras in signal transduction. Semin Cancer Biol 3 (1992) 169-177
160. Campbell S.L., Khosravi-Far R., Rossman K.L., Clark G.J., and Der C.J. Increasing complexity of Ras signaling. Oncogene 17 (1998) 1395-1413
161. Chang F., Steelman L.S., Shelton J.G., et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol 22 (2003) 469-480
162. Rodenhuis S. Ras and human tumors. Semin Cancer Biol 3 (1992) 241-247
163. Zachos G., and Spandidos D.A. Expression of ras proto-oncogenes: regulation and implications in the development of human tumors. Crit Rev Oncol Hematol 26 (1997) 65-75
164. Friday B.B., and Adjei A.A. K-ras as a target for cancer therapy. Biochim Biophys Acta 1756 (2005) 127-144
165. Scheffzek K., Ahmadian M.R., Kabsch W., et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277 (1997) 333-338
166. Moon A. Differential functions of Ras for malignant phenotypic conversion. Arch Pharm Res 29 (2006) 113-122
167. Campbell P.M., and Der C.J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin Cancer Biol 14 (2004) 105-114
168. Minamoto T., Mai M., and Ronai Z. K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers-a review. Cancer Detect Prev 24 (2000) 1-12
169. Keohavong P., Mady H.H., Gao W.M., et al. Topographic analysis of K-ras mutations in histologically normal lung tissues and tumours of lung cancer patients. Br J Cancer 85 (2001) 235-241
170. Vachtenheim J. Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma 44 (1997) 145-149
171. Mills N.E., Fishman C.L., Rom W.N., Dubin N., and Jacobson D.R. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55 (1995) 1444-1447
172. Ramakrishna G., Sithanandam G., Cheng R.Y., et al. K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res 26 (2000) 659-671
173. Miyamoto H., Harada M., Isobe H., et al. Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer. Cancer Res 51 (1991) 6346-6350
174. Mascaux C., Iannino N., Martin B., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92 (2005) 131-139
175. Mitsudomi T., Viallet J., Mulshine J.L., et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6 (1991) 1353-1362
176. Wagner S.N., Muller R., Boehm J., et al. Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. Virchows Arch B Cell Pathol Incl Mol Pathol 63 (1993) 325-329
177. Khanzada U.K., Pardo O.E., Meier C., et al. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene 25 (2006) 877-887
178. Bartling B., Yang J.Y., Michod D., et al. RasGTPase-activating protein is a target of caspases in spontaneous apoptosis of lung carcinoma cells and in response to etoposide. Carcinogenesis 25 (2004) 909-921
179. Friedman E. The role of ras GTPase activating protein in human tumorigenesis. Pathobiology 63 (1995) 348-350
180. Yang J.Y., and Widmann C. Antiapoptotic signaling generated by caspase-induced cleavage of RasGAP. Mol Cell Biol 21 (2001) 5346-5358
181. Basso A.D., Kirschmeier P., and Bishop W.R. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 47 (2006) 15-31
182. Sepp-Lorenzino L., Ma Z., Rands E., et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55 (1995) 5302-5309
183. Heymach J.V., Johnson D.H., Khuri F.R., et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 15 (2004) 1187-1193
184. Matsumoto S., Kimura S., Segawa H., et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 47 (2005) 31-39
185. Ural A.U., and Avcu F. Radiosensitizing effect of zoledronic acid in small cell lung cancer. Lung Cancer 50 (2005) 271-272
186. Ory B., Heymann M.F., Kamijo A., et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104 (2005) 2522-2529
187. Ben-Ezra J.M., Kornstein M.J., Grimes M.M., and Krystal G. Small cell carcinomas of the lung express the Bcl-2 protein. Am J Pathol 145 (1994) 1036-1040
188. Ikegaki N., Katsumata M., Minna J., and Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 54 (1994) 6-8
189. Higashiyama M., Doi O., Kodama K., Yokouchi H., and Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res 15 (1995) 503-505
190. Jiang S.X., Sato Y., Kuwao S., and Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 177 (1995) 135-138
191. Paik K.H., Park Y.H., Ryoo B.Y., et al. Prognostic value of immunohistochemical staining of p53, bcl-2, and Ki-67 in small cell lung cancer. J Korean Med Sci 21 (2006) 35-39
192. Takayama K., Ogata K., Nakanishi Y., et al. Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. Cancer J Sci Am 2 (1996) 212-216
193. Zereu M., Vinholes J.J., and Zettler C.G. p53 and Bcl-2 protein expression and its relationship with prognosis in small-cell lung cancer. Clin Lung Cancer 4 (2003) 298-302
194. Stefanaki K., Rontogiannis D., Vamvouka C., et al. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. Anticancer Res 18 (1998) 1167-1173
195. Sartorius U.A., and Krammer P.H. Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97 (2002) 584-592
196. Ohmori T., Podack E.R., Nishio K., et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192 (1993) 30-36
197. Ziegler A., Luedke G.H., Fabbro D., et al. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89 (1997) 1027-1036
198. Zangemeister-Wittke U., Schenker T., Luedke G.H., and Stahel R.A. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 78 (1998) 1035-1042
199. Webb A., Cunningham D., Cotter F., et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349 (1997) 1137-1141
200. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
201. Gekeler V., Gimmnich P., Hofmann H.P., et al. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice. Oligonucleotides 16 (2006) 83-93
202. Rudin C.M., Otterson G.A., Mauer A.M., et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 13 (2002) 539-545
203. Rudin C.M., Kozloff M., Hoffman P.C., et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 22 (2004) 1110-1117
204. Cappuzzo F., Gregorc V., Rossi E., et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21 (2003) 2658-2663
205. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
206. Sjoblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
207. Guerreiro A.S., Boller D., Shalaby T., Grotzer M.A., and Arcaro A. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition. Int J Cancer 119 (2006) 2527-2538
208. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
209. Browd S.R., Kenney A.M., Gottfried O.N., et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res 66 (2006) 2666-2672
210. Dooley S., Wundrack I., Blin N., and Welter C. Coexpression pattern of c-myc associated genes in a small cell lung cancer cell line with high steady state c-myc transcription. Biochem Biophys Res Commun 213 (1995) 789-795
211. Levin N.A., Brzoska P., Gupta N., et al. Identification of frequent novel genetic alterations in small cell lung carcinoma. Cancer Res 54 (1994) 5086-5091
212. Wang M.Y., Lu K.V., Zhu S., et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66 (2006) 7864-7869
213. Kohno T., Takahashi M., Manda R., and Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22 (1998) 152-156